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Abstract 
Surfactant protein B (SP-B, gene name: sftpb) is essential for normal lung function. It 
reduces alveoli surface tension, thereby preventing the lung from collapse. A single 
nucleotide polymorphism (SP-B 1580 C/T) is associated with several lung diseases and 
altered N-linked glycosylation site at Asn
129
 of SP-B. This change, present in the human 
population, has been associated with negative effects on SP-B precursor (proSP-B) 
processing and function. In this study, hSP-B humanized transgenic mice were generated 
without mouse SP-B background. Four founding lines, showing only the hSP-B gene, 
were selected via PCR-based DNA analysis. Genomic sequencing of these mice revealed 
which allele variant (hSP-B-C/T) they carried. Western blot analysis of BALF samples 
revealed these hTG mice expressed hSP-B protein in levels significant for survival and 
comparable to that of a healthy human lung. Characterization of the two hSP-B allele 
variant hTG strains revealed significant differences in their relative alveolar size and total 
lipid concentration.  
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Executive Summary 
 
 
Surfactant protein B (SP-B, genus name: sftpb) is a vital component of a healthy and 
normally functioning lung. It coats the surface of alveoli and prevents them from 
collapsing by lowering surface tension. Alveoli, hollow sacs found in the lung, are the 
site of oxygen and carbon dioxide exchange in the body. Modification of the gene that 
codes for this protein can lead to its dysfunction and cause serious, even fatal, lung 
complications. This paper looks to analyze one such modification. SP-B gene encodes a 
protein that is 381 amino acids (building blocks of protein) in length. A single nucleotide 
change (from ‘T’ to ‘C’) in the DNA changes one of these amino-acids from a Threonine 
to an Isoleucine. This small change has a drastic effect on how the protein folds together 
and subsequently how it performs. The two forms (alleles) of this gene are labeled C-
allele (SP-B-C), which contains the modification, and wild type (normal) T-allele variant 
(SP-B-T) which does not. This change, which has been associated with decreased lung 
function, is common in the human population and represents an important avenue of 
research.  
To study the effect this genetic modification has on physiological function and structure, 
humanized transgenic mice (hTG) were created. hTG SP-B mice express human SP-B 
(hSP-B) but not mouse SP-B (mSP-B). To generate these mice, the human SP-B gene 
was inserted into mouse oocytes. These mice, which now contain both the mouse SP-B 
gene and human gene, were bred with ‘knockout’ mice (KO) that did not express either 
form of the gene. From the resulting offspring, mice that expressed only the human gene, 
and not the mouse SP-B gene, were selected for testing in this experiment. This selection 
was accomplished by taking tail samples and testing the DNA for mice that were human 
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SP-B conditional. This test confirmed that the human gene had successfully been inserted 
into the (now humanized transgenic) mice and was being expressed at levels sufficient 
for survival. Four ‘Founder’ strains had been selected and were given labels: 2004, 2007, 
2012, and 2059. Next, the DNA from each of these four founder strains was sequenced to 
see if they contained the SP-B gene modification. Of the four strains, only one (2012) 
was determined to contain the C-allele while the rest (2004, 2007, 2012) contained the   
T-allele.  
The goal of this paper was to characterize the hSP-B gene successfully established in 
these humanized transgenic mice and to compare the two allele variants (C/T) to samples 
taken from a healthy human. The following factors were tested: relative size of alveoli, 
SP-B expression levels, and total lipid concentration. Alveolar size was tested by taking 
lung samples from each of the four founder strains and viewing them under a microscope.  
Relative size was then determined by superimposing these images over a grid and 
counting the number of intersections (‘hits’) that each alveolus contained. 100 alveoli 
from each founder strain were tested and used to calculate average size. Results indicated 
that mice containing the C-allele (hSP-B-C) had significantly larger alveoli compared to 
those containing the T-allele (hSP-B-T). Protein expression levels and lipid concentration 
were determined by testing broncho-alveolar lavage fluid (BALF). BALF is obtained by 
injecting a sterilized solution into the lung and withdrawing it back (now containing lung 
material) for use in further testing. The level of hSP-B expression in the hTG mice was 
determined using western blot analysis. In this method, proteins are separated by their 
molecular weight. Since the molecular weight of human SP-B is known, western blot 
analysis allowed not only for confirmation that hSP-B was being expressed by the mice 
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but also to what extent. Results of this testing indicated that the level of hSP-B protein 
expression in the lung of these transgenic mice is comparable with that in the human 
lung. Lipid concentration was determined by testing the degree to which these samples 
could absorb UV light. These results indicated that the level of lipid concentration was 
significantly higher in the BALF taken from a C-allele mouse compared to that of the T-
allele variant and also to that found in a healthy human. The T-allele showed comparable 
lipid concentration to that of the human sample.  
In summary, humanized transgenic mice were generated that carried human SP-B          
C-allele or T-allele. hSP-B expression levels were sufficient for survival and were 
comparable with that in the human lung. Characterization of these hSP-B two allele 
variants reveled significant differences in their relative alveolar size and total lipid 
concentration.  
These differences should help drive the future research needed to ascertain the specific 
nature of the C-allele’s negative effect on the host’s ability to fight respiratory diseases. 
Since this mutation is common in the human population, the ability to identify patients 
containing this C-allele variant could lead to modified treatment and an increased success 
rate in fighting their respiratory disease.  
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Introduction 
Surfactant protein B (SP-B gene name: sftpb) is essential for effective pulmonary 
respiration and physiological function. Pulmonary surfactant, a lipid and protein complex 
synthesized by alveolar type II cells, lines alveoli at the gas-liquid interface and reduces 
surface tension, thereby preventing the lung from collapse. Surface tension arises as 
water molecules are more strongly attracted to one another than to air molecules causing 
an inwardly directed force that tends to reduce surface area [1]. During low lung volumes 
(expiration), surfactant is squeezed out of the surface of the alveoli and forms micelles. 
Upon inspiration, this film is spread over the surface of the alveoli reducing surface 
tension and maintaining the structural integrity of the lung. Surfactant-associated protein 
is made up of four primary functional components: surfactant protein A (SP-A), 
surfactant protein B (SP-B), surfactant protein C (SP-C), and surfactant protein D (SP-D). 
Surfactant proteins A and D are important in immunity and host defense while SP-B is a 
vital structural component of the surfactant. SP-B loss of function causes surfactant death 
and subsequently alveolar collapse and decreased lung function. Human SP-B (hSP-B) 
genetic variation has been associated with several fatal respiratory diseases, such as 
congenital alveolar proteinosis [2-4], and SP-B-deficient mice exhibit pulmonary 
dysfunction and die shortly after birth [5]. Two variants will be examined in this paper: T 
allele and C allele. A single nucleotide polymorphism (SN, rs1130866) SP-B 1580 C/T 
alters N-linked glycosylation of Asn
129
, which is present in the C allele but absent in the 
T allele [6]. This alteration in N-linked glycosylation pattern may influence SP-B 
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precursor processing and function. hSP-B precursor contains three Saposin-like protein 
(SAPLIP) domains, SP-B
N
, SP-B
M
, and SP-B
C
. N-Linked glycosylation occurs in the SP-
B
N
 domain. For this study, humanized transgenic mice were successfully generated that 
contain either the C or T allele of the human SP-B gene without mouse SP-B background. 
Transgenic mice showed comparable hSP-B expression with that in the human lung and 
also showed normal phenotypes as wild type (WT) mice. These results indicate that   
hSP-B is functional in the transgenic mice. The goal of this study was to characterize this 
humanized sftpb transgenic mouse line.  
 
Materials and Methods  
Mice and animal husbandry 
Wild type mice used for this study were purchased from the Jackson Laboratory (Bar 
Harbor, ME). They were then maintained in the animal core facility of SUNY Upstate 
Medical University (SUNY UMU) throughout the duration of the study. hTG SP-B mice 
generated for this study were conditional hSP-B transgenic mice (contained the 
background of SP-B KO mice). All mice used for this study were handled by the 
protocols approved by the Institutional Animal Care and Use Committee of SUNY 
UMU. 
 
Constructs for generation of TG SP-B and conditional TG SP-B mice 
To generate hSP-B mice, the cDNA of human sftpb had to first be cloned into a suitable 
vector and initiated by a human promoter. This was accomplished by cloning the cDNA 
into a basic 3.7-hSP-C/SV40 plasmid. A 5.4 kb DNA fragment of this vector was then 
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excised from the recombinant plasmids and microinjected into fertilized FVB/N oocytes 
from wild type mice.  
 
Generation of hTG SP-B Mice 
The generation of an hTG SP-B strain began by mating mice which carried both the 
mouse and human genes (hSP-B+/-, mSP-B+/+) with SP-B KO mice which expressed 
neither gene (hSP-B-/-, mSP-B-/-). This yielded hTG SP-B F1 mice (hSP-B+/-, mSP-
B+/-). This strain was then mated with SP-B KO mice to block the mouse SP-B gene. 
KO mice (conditional transgenic) could not express mSP-B due to a neomycin resistant 
gene that was inserted into exon 4 of their SP-B gene. Finally, homozygous hTG hSP-B 
mice could be obtained by the self breeding of F2 mice from the same founder. hTG  
SP-B mice were therefore defined as being human SP-B positive and mouse SP-B 
negative (hSP-B +/+, mSP-B-/-) 
 
Genotype analysis of the hTG SP-B mice 
Genotyping was required to correctly identify the hTG SP-B mice. 0.5-1.0cm tail 
samples were obtained from new born pups after being weaned from their parents using 
a Qiagen DNeasy kit (Qiangen, Valencia, CA). The quality of the DNA was analyzed 
using Nano Drop. Two Polymerase Chain Reactions (PCR) amplifications were 
performed using the same DNA sample as the template: primer pair 1458/189 (which 
was used to screen hSP-B) and primer pair 75/76 (which was used to amplify mSP-B). 
Conditions for the running of the PCR were as follows: 95°C for 2 minutes, then 95°C 
for 40s, 58°C for 40s, and 68°C for 40s.This cycle was run 35 times with the final 
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extension step being performed for 7 minutes at 68°C. Products of this PCR were then 
examined utilizing 2% agarose gel electrophoresis and an EB stain solution. Only 
samples that showed the hSP-B band exclusively were labeled as human SP-B positive 
and mouse SP-B negative. To identify the polymorphism allele at site +1580, primer 
pair 1458/1401 was used to amplify the whole fragment of hSP-B gene from the positive 
DNA samples by High Fidelity PCR kit (Roche). The PCR for this sample was varied 
from the reaction prior. Initial denaturation was run for 2 minutes at 94°C followed by 
10 cycles of the following conditions: 94°C 30s, 58°C 30s and 72°C 2 minutes. This was 
followed by two cycles of:  94°C 30s, 58°C 30s and 72°C 3 minutes. The final step was 
extension at 72°C for 7 minutes. The PCR products were sequenced by the Core Facility 
of SUNY Upstate Medical University. 
 
 
Western blot analysis of surfactant proteins from mouse BALF  
Western blot analysis was performed on the broncho-alveolar lavage fluid (BALF) of 
positive mice to identify expression levels of human SP-B protein in hTG SP-B mice. 
Samples were taken from mice (8-12 weeks) and lavaged with 0.5 mL of autoclaved 
PBS solution. Total protein concentration of the BALF was measured by BCA micro 
assay kit (Thermo). 10 µg of total protein was loaded on a 12% non-reducing SDS-
PAGE gel. 10 µg of human BALF was also loaded onto the gel for use as a positive 
control. Electrophoresis was run on the samples at 60V for 30 minutes followed by 
110V for 1 hour. The human SP-B protein was identified by anti-pig SP-B antibodies as 
well as two others, labeled as Antibody 1 and Antibody 2, which were created in the lab 
for use on this protein. Antibodies were used at 1:5000 and 1:10000 dilutions.  
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Histological and cellular analysis  
To observe the histological structure and determination of relative alveolar size, lungs 
from positive mice (C and T allele) were fixed by 10% formalin solution at about 25 cm 
of water pressure, and then processed into paraffin blocks. Blocks were cut into pieces 
with thickness of roughly 5 µm. Sections were stained by hematoxylin and eosin kit 
while others were stained with ABC kit (Vector Laboratories, Burlingame, CA). 
 
 Determination of Relative Alveolar Size using Delesse Method 
 Samples prepared for histological and cellular analysis placed on microscope slides and 
viewed using a Nikon Eclipse TE2000-U microscope at 20x magnification. To conduct 
the Delesse Method of determining relative alveolar size, the images were superimposed 
on a grid. From this grid, the number of intersections (‘hits’) that each alveolus contained 
was counted. 100 alveoli were used for each founder strain and used to calculate average 
size.  
 
Determination of Lipid Concentration from BALF 
BALF samples from each founder variant (CT) and from a healthy human had to first be 
diluted to 1:10 adequate detection and determination of lipid concentration (mg/mL). 
For each sample, 15 µL of BALF was added to 135 µL of PBS buffer and the resulting 
solution was loaded into a Multiskan Ascent V1.24 to determine absorbance. To 
determine lipid concentration, absorbance of the samples were compared to the known 
absorbance of albumin at a preset concentration. Lipid concentration of each variant 
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strain of hTG mice (hSP-B-C/T) were compared to one another and also to that of the 
sample from a healthy human.  
*  All experiments were repeated at least three times. Western blot bands were quantified 
by Quantity One (version 4.6.1). Statistical analysis was performed by Sigma Stat version 
3.5 software. Significant difference in statistics among groups was considered when        
p < 0.05 by t-test or ANOVA 
 
Results 
 
1. Generation of SP-B-T and SP-B-C mice and transgene transmission in the 
offspring 
The generation of human SP-B transgenic mice began by cloning the cDNA of human 
sftpb into a basic 3.7-hSP-C/SV40 vector and driven by the human sftpb promoter. A   
5.4 kb DNA fragment was then excised from the recombinant plasmid and microinjected 
into fertilized FVB/N oocytes from wild type mice. Four founder lines of hTG SP-B mice 
were generated and identified by PCR amplification of DNA fragment of SP-B: 2004, 
2007, 2012, and 2059. Endogenous mouse SP-B background was eliminated by the use of 
conditional human SP-B transgenic mice, while expression of the mouse SP-B gene was 
shut down by the insertion of a Neomycin resistant gene into SP-B exon 4. These mice 
were named as KO (hSP-B -/mSP-B -). Next, an F1 generation of hTG mice (hSP-B 
+/mSP-B +) was generated by the mating of these conditional human SP-B transgenic 
mice with hSP-B positive transgenic founders. Positive mice in the F1 generation were 
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then bred with KO mice to generate a line of F2 positive mice (hSP-B+/mSP-B-). 
Summary of this breeding process can be seen below in Figure 1: 
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Genotype analysis was then conducted via PCR to amplify fragments of both the mSP-B 
and hSP-B. hSP-B was amplified with primer pair 1458/1401 locating on the SP-C 
promoter and the 3’ end of SP-B cDNA respectively. Amplification of this gene yields a 
PCR product of 577bp. Conversely, mSP-B was amplified with primers 75 and 76 which 
locate the 3’ end of intron 3 and the 5’ end of intron 4 respectively. Amplification of this 
gene leaves a product that is 279 bp. Humanized SP-B mice showing only the hSP-B 
band (577 bp) were were selected out of this F2 generation and used for this study            
(Figure 2).  
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Genetic sequencing of these mice (labeled F3) was conducted to detect the presence of a 
single-nucleotide polymorphism (SNP) in SP-B gene exon 4 position 1580 (Figure 3A). 
The T/C allele variation changes amino acid 131, causing a change from threonine to 
isoleucine (Thr
131
-Ile). This change eliminates an N-linked glycosylation site, Asn
129
-
Gln-Thr
131
, present in the C allele (hSP-B-C) but not the wild type T allele (hSP-B-T). It 
has been reported that the C allele is associated with increased risk of acute respiratory 
distress syndrome (ARDS) and respiratory failure in adults [7-8]. Samples were sent from 
each founder strain to the University’s Core facility for sequencing analysis. The data 
reported that three of the 4 founders (2004, 2007, 2059) carried the T allele while founder 
2012 carried the lone C allele (Figure 3B). 
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2.  Comparison of alveolar size in hSP-B-C and hSP-B-T transgenic mice. 
To compare the relative size of alveoli between humanized transgenic mice, lung tissue 
was harvested from each of the four founder strain (8-12 weeks). Samples were fixed by 
10% formalin solution at about 25 cm of water pressure and then processed into paraffin 
blocks. From these blocks, 5 µm thick sections were cut, placed on microscope slides, 
and stained by hematoxylin and eosin staining kits. Relative size of alveoli was 
estimated using the Delesse Method in which microscopic images of alveoli cells were 
superimposed on a grid. From this grid, the number of line intersections (hits) within 
each alveoli was counted and averaged for each founder strain thus estimating relative 
differences in total size the alveoli themselves. All images were taken when viewed at 
20x magnification on a Nikon Eclipse TE2000-U microscope and overlain on the same 
grid. For each founder, 50 alveoli from two separate mice were sampled and used for 
calculation. The results (Figure 4) indicate a sizable difference in the relative size of 
alveoli between hSP-B-C and hSP-B-T transgenic mice.  
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3. Western Blot Analysis 
 
SP-B gene codes a 381 amino acid long precursor (pro-SP-B) that has a molecular mass 
of 42 kDa. This proSP-B undergoes extensive post-translational processing (See Figure 
5) to yield mature SP-B (region comprising 201-279) which has a molecular mass of 8 
kDa and is found in broncho-alveolar lavage material.  
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Processing of proSP-B includes cleavage of signal peptides, glycosylation of C-terminus, 
and cleavage of N and C terminal propeptides [9]. Pepsinogen C is an aspartyl protease 
that has been identified as an important player in this post-translational modification by 
cleaving proSP-B at Met
302
 and Ser
197
 [10]. Western Blot analysis of BAL fluid was 
conducted to determine the extent of hSP-B gene expression in each of the four strains of 
hTG mice. BAL fluid and lung tissue were prepared from each founder and compared to 
the BAL fluid from a healthy adult which was used as a positive control. Human SP-B 
gene was identified by used of 3 antibodies: Alpha-pig antibody, Antibody 1, and 
Antibody 2. Alpha-pig is a commercially purchased identification antibody that detects 
mature SP-B. Non-reducing gel for was used for these samples as it allowed for better 
detection. As a result, mature SP-B presented as a dimer and showed a band at 16 kDa 
instead of its actual molecular mass of 8 kDa. Antibodies 1 and 2 are used to detect 
proSP-B and fragments of partially processed SP-B (42, 28 kDa). Our results indicate 
that human SP-B was successfully integrated and expressed in hTG mice at levels 
sufficient for survival (see figure 6-8). Bands of known molecular mass, corresponding to 
regions in proSP-B and mature SP-B, were seen in both human BAL fluid samples as 
well as in each hTG mouse strain. Quantification of hSP-B expression was then 
conducted using Quantity One software (version 4.6.1). Results of this analysis indicate 
that hSP-B was expressed in both variants (C/T) of hTG mice in comparable levels to that 
found in human BAL fluid (see Figure 9). 
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Figures 6-8  Western Blot Analysis 
hSP-B expression in hTG mice was confirmed through western blot testing of BALF 
samples taken from each of the four Founder strains (2004, 2007, 2012, 2059). 20µg of 
total protein from F2 mice of 4 different founders was subjected to 12% SDS-PAGE 
under non-reducing condition. A human BALF was used as a positive control Gels were 
subjected to one of four different antibodies used for identification. Figures 6 shows both 
sham and infected (pneumonia) mouse BALF detected with AB1 which identifies proSP-
B (42 kDa). Figure 7 shows the same samples when detected by AB2 which also identifies 
portions of proSP-B (28 kDa). Figure 8 shows the dimer (a 16kD band) of mature hSP-B 
after being detected with Alpha-pig antibody These results indicate all four of founders 
can express sufficient hSP-B protein for survival. 
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4. Lipid Concentration  
 
Total lipid concentration was determined from BAL fluid samples from both variant 
strains of hTG mice (hSP-B-C/T) and compared to that of BAL fluid taken from a 
healthy human. Samples were diluted to 1:10 by PBS and run through a Multiskan 
Ascent V1.24. Samples were compared to albumin which served as the calibration blank. 
Results (Figure 11) showed that the T variant (2007) showed comparable lipid 
concentration levels (0.0708 ± 0.00203 mg/ml) to that of the human sample (0.054 
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mg/ml) while the C variant (2012) showed significantly higher lipid concentration 
(0.13825 ± 0.00256 mg/ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
Surfactant Protein B (SP-B), a lipid protein complex, plays a critical role in the lung’s 
physiological function and structural integrity by reducing alveolar surface tension. A 
single polymorphism SP-B (1580 C/T) causes the change of amino acid 131 from 
threonine to isoleucine (Thr
131
-Ile). This change alters N-linked glycosylation which may 
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in turn alter SP-B precursor (proSP-B) post-translational processing and function. This 
glycosylation, which occurs at Asn
129
, is present in the C-allele variant (hSP-B-C) but is 
absent in the T-allele variant (hSP-B-T). It has been reported that the C-allele is 
associated with increased risk of ARDS and other respiratory conditions in adults.  
Generation of an hTG mouse line, containing hSP-B without background mSP-B, began 
by the cloning of human sftpb cDNA into a suitable vector and initiated by a human 
promoter. A DNA fragment of the recombinant plasmid was microinjected into fertilized 
WT mouse oocytes. These mice, now containing both the mouse and human SP-B gene 
were bred with conditional transgenic mice (KO) to remove the mSP-B background 
(Figure 1). SP-B fragment in the KO mice could not be expressed due to a neomycin 
resistance gene that was inserted into their SP-B gene. Mouse tail samples were collected 
from these transgenic mice and genotyped along with positive and negative controls by 
amplification of both human SP-B and mouse SP-B fragments via PCR (Figure 2). Mice 
that showed the hSP-B gene without mSP-B background (hSP-B+/mSP-B-) were selected 
and used in this study. Of this group, four Founder strains were selected (2004, 2007, 
2012, 2059) and subjected to genetic sequencing. This sequencing was performed to 
identify the C/T allele variant type of each Founder strain. Only the 2012 strain showed 
the C-allele while the other three strains exhibited the T-allele (Figure 3). After 
identifying the gene in the four Founder strains, attention shifted to characterization of 
hSP-B in these hTG mice. Comparison of alveolar size was conducted via the Delesse 
Method. Results (Figure 4) indicated that the 2012 C-allele variants have significantly 
larger alveoli (26.98±1.227 hits/alveoli) than any of the T-allele variant strains. Western 
Blot Analysis was performed to identify expression of the hSP-B in the BALF of hTG 
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Founder strains. SP-B gene codes a 381 amino-acid precursor that undergoes extensive 
post-translational modification (Figure 5). Three antibodies (AB1, AB2, Alpha-pig) were 
used for detection of both pro-SP-B and mature SP-B fragments. Results show that hSP-
B was expressed in all of the founder strains at levels sufficient for survival (Figures 6-9). 
To compare SP-B expression levels with those found in humans, quantification of the 
western blot bands was performed. Scans of the western blot gels were subjected to 
analysis by Quantity One software. Results of the quantification (Figure 10) indicate that 
hSP-B was expressed in the four Founder hTG mice in comparable levels to that of the 
human sample (positive control). BALF samples from each variant type (C/T) were then 
subjected to lipid concentration testing and compared BALF from a healthy human. 
Albumin was used as the calibration blank. Results indicate that the 2012 C-allele variant 
exhibited significantly higher lipid concentration than either the T-allele variant or human 
sample. The T-allele variant and the human sample exhibited similar concentration levels 
(Figure 11). 
 
Conclusion 
Humanized sftpb transgenic founder lines carrying the human SP-B C allele or T allele 
were generated and showed normal phenotypes as WT mice. The level of hSP-B protein 
expression in the lungs of these transgenic mice is comparable with that in the human 
lung indicating hSP-B is functional within these founder lines. Characterization of the 
two hSP-B allele hTG strains revealed significant differences in their relative alveolar 
size and total lipid concentration. These differences should help drive the future research 
needed to ascertain the specific nature of the C-allele’s negative effect on the host’s 
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ability to fight respiratory diseases. Since this mutation is common in the human 
population, the ability to identify patients containing this C-allele variant could lead to 
modified treatment and an increased success rate in fighting their respiratory disease.  
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